A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

This study has been completed.
Sponsor:
Collaborator:
Targacept Inc.
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01152554
First received: June 28, 2010
Last updated: March 14, 2014
Last verified: March 2014
  Purpose

The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken for 52 weeks with another antidepressant medicine.


Condition Intervention Phase
Major Depressive Disorder
MDD
Depression
Drug: TC-5214
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients With Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Frequency of Patients Experiencing at Least One Adverse Event (AE) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing at least one AE during the randomized treatment or follow-up periods was calculated.

  • Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing AEs that resulted in discontinuation of IP during the randomized treatment or follow-up periods was calculated.

  • Frequency of Patients Experiencing Serious Adverse Events (SAEs) [ Time Frame: Randomization (Week 0) to end of the follow-up period (Week 54) ] [ Designated as safety issue: No ]
    The frequency of patients experiencing serious adverse events (SAEs) during the randomized treatment or follow-up periods was calculated.


Secondary Outcome Measures:
  • Sustained Efficacy at 3 Months, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤12 at Week 12 and All Visits up to and Including Week 24 [ Time Frame: Week 12 to Week 24 ] [ Designated as safety issue: No ]

    The percentage of patients with a a MADRS total score of ≤12 at Week 12 and all visits up to and including Week 24 was calculated. One intermediate occurrence of a MADRS total score >12 but ≤16 or missing was allowed from Week 16 to Week 20.

    A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.


  • Sustained Efficacy at 9 Months, Defined as a MADRS Total Score of ≤12 at Week 12 and at All Visits up to and Including Week 52 [ Time Frame: Week 12 to Week 52 ] [ Designated as safety issue: No ]

    The percentage of patients with a MADRS total score of ≤12 at Week 12 and at all visits up to and including Week 52 was calculated. Two intermediate occurrences (not consecutive) of a MADRS >12 but ≤16 or missing were allowed from Week 16 to Week 48.

    A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.


  • Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 0) to End of Treatment (Week 52) [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline). Each item is scored on a 1 to 7 scale. Higher CGI-S scores indicate greater illness severity.

  • Change in Functional Impairment From Randomization (Week 0) to End of Treatment (Week 52) as Measured by the Sheehan Disability Scale (SDS) Total Score [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    Sheehan Disability Scale (SDS) is 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The SDS total score is calculated as the sum of the score for the 3 inter-correlated domains (school/work, social life, and family life/home responsibilities) and ranges from 0 (unimpaired) to 30 (highly impaired).

  • Change in Overall Quality of Life and Satisfaction From Randomization (Week 0) to End of Treatment (Week 52) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    The Q-LES-Q-SF total score is derived by summing item scores 1 to 14. Higher scores are indicative of greater enjoyment or satisfaction in each domain. The Q-LES-Q-SF % maximum total score is calculated as 100% × (Q-LES-Q-SF total score - 14) / 56, and can range from 0% to 100%.

  • Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 0) to End of Treatment (Week 52) [ Time Frame: Randomization (Week 0) to end of treatment (Week 52) ] [ Designated as safety issue: No ]
    A self-assessment questionnaire that provides 2 measures of health status. The EQ-5D index score is a weighted linear combination over 5 dimensions of health status. The score for each of the 5 dimensions can range from 1 to 3, and an equation is used to calculate the EQ-5D index score. The EQ-5D index score can range from possible negative values to a maximum of 1.0. The EQ-VAS is a visual analog scale with a range of 0 to 100. For both variables, a higher score indicates a better health state.


Enrollment: 813
Study Start Date: June 2010
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SSRI/Serotonin/SNRI + TC-5214 1-4 mg
Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
Drug: TC-5214
Tablet, oral, twice daily for 52 weeks
Placebo Comparator: SSRI/Serotonin/SNRI + placebo
Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
Drug: Placebo
Tablet, oral, twice daily for 52 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent before initiation of any study-related procedures.
  • The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.
  • Outpatient status at enrollment and randomization.

Exclusion Criteria:

  • Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.
  • Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide.
  • Patients with significant liver, kidney, lung, heart, neurological, or any other medical conditions that might confound the study or put the patient at greater risk during study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01152554

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
Research Site
Tuscaloosa, Alabama, United States
United States, Arizona
Research Site
Tucson, Arizona, United States
United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Arcadia, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Carson, California, United States
Research Site
Cerritos, California, United States
Research Site
Chino, California, United States
Research Site
Costa Mesa, California, United States
Research Site
Encino, California, United States
Research Site
Escondido, California, United States
Research Site
Garden Grove, California, United States
Research Site
Irvine, California, United States
Research Site
Los Alamitos, California, United States
Research Site
Los Angeles, California, United States
Research Site
Newport Beach, California, United States
Research Site
Pico Rivera, California, United States
Research Site
Riverside, California, United States
Research Site
Sherman Oaks, California, United States
Research Site
Torrance, California, United States
Research Site
Upland, California, United States
United States, Colorado
Research Site
Denver, Colorado, United States
United States, Connecticut
Research Site
Norwalk, Connecticut, United States
Research Site
Norwich, Connecticut, United States
United States, Florida
Research Site
Bradenton, Florida, United States
Research Site
Coral Springs, Florida, United States
Research Site
Ft Myers, Florida, United States
Research Site
Gainsville, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
North Miami, Florida, United States
Research Site
Orange City, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Pinecrest, Florida, United States
Research Site
Plantation, Florida, United States
Research Site
St Petersburg, Florida, United States
Research Site
Tampa, Florida, United States
Research Site
West Palm Beach, Florida, United States
United States, Georgia
Research Site
Roswell, Georgia, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
Research Site
Hoffman Estates, Illinois, United States
Research Site
Joliet, Illinois, United States
Research Site
Schaumburg, Illinois, United States
Research Site
Skokie, Illinois, United States
United States, Indiana
Research Site
Lafayette, Indiana, United States
Research Site
Valparaiso, Indiana, United States
United States, Kansas
Research Site
Prairie Village, Kansas, United States
Research Site
Wichita, Kansas, United States
United States, Kentucky
Research Site
Florence, Kentucky, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
United States, Maryland
Research Site
Baltimore, Maryland, United States
Research Site
Gaithersburg, Maryland, United States
Research Site
Glen Burnie, Maryland, United States
Research Site
Rockville, Maryland, United States
United States, Massachusetts
Research Site
Weymouth, Massachusetts, United States
United States, Mississippi
Research Site
Flowood, Mississippi, United States
United States, Missouri
Research Site
Creve Coeur, Missouri, United States
Research Site
St. Louis, Missouri, United States
United States, Nebraska
Research Site
Lincoln, Nebraska, United States
United States, New Jersey
Research Site
Toms River, New Jersey, United States
Research Site
Willingboro, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
Fresh Meadows, New York, United States
Research Site
Mount Kisco, New York, United States
Research Site
New York, New York, United States
Research Site
Rochester, New York, United States
Research Site
Staten Island, New York, United States
United States, North Carolina
Research Site
Charlotte, North Carolina, United States
Research Site
Wilmington, North Carolina, United States
United States, Ohio
Research Site
Beechwood, Ohio, United States
Research Site
Canton, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Dublin, Ohio, United States
Research Site
Mason, Ohio, United States
Research Site
Middleburg Heights, Ohio, United States
Research Site
Toledo, Ohio, United States
United States, Oregon
Research Site
Portland, Oregon, United States
Research Site
Salem, Oregon, United States
United States, Pennsylvania
Research Site
Jenkintown, Pennsylvania, United States
Research Site
Norristown, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Friendswood, Texas, United States
Research Site
Irving, Texas, United States
Research Site
Lake Jackson, Texas, United States
Research Site
San Antonio, Texas, United States
United States, Vermont
Research Site
Woodstock, Vermont, United States
United States, Washington
Research Site
Seattle, Washington, United States
Research Site
South Kirkland, Washington, United States
United States, Wisconsin
Research Site
Middleton, Wisconsin, United States
Puerto Rico
Research Site
San Juan, Puerto Rico
Sponsors and Collaborators
AstraZeneca
Targacept Inc.
Investigators
Study Director: Hans A. Eriksson, MD, Ph.D, MBA AstraZeneca
Principal Investigator: Andrew . J Cutler, MD Florida Clinical Research Center, LLC
  More Information

Additional Information:
No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01152554     History of Changes
Other Study ID Numbers: D4130C00007
Study First Received: June 28, 2010
Results First Received: June 26, 2012
Last Updated: March 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Major Depressive Disorder
MDD
Depression
Safety
add-on therapy

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Major
Disease
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes
Serotonin
Serotonin Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin Agents
Serotonin Receptor Agonists

ClinicalTrials.gov processed this record on October 29, 2014